



Drug Quantity Management – Per Days Calcitonin Gene-Related Peptide Inhibitors – Aimovig

Table of Contents

National Formulary Medical Necessity 1
 Conditions Not Covered.....2
 Background.....2
 References2
 Revision History.....2

Product Identifier(s)

Effective 1/1/23 to 2/6/23: 107362
Effective 2/7/23: 80497

INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

Drugs Affected

- Aimovig® (erenumab-aooe subcutaneous injection)

This Drug Quantity Management program has been developed to manage potential dose escalation of Aimovig in the treatment of migraine and to provide a sufficient quantity for indications covered by the *Calcitonin Gene-Related Peptide Inhibitors – Aimovig Prior Authorization Policy*. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below.

Drug Quantity Limits

Product	Strength and Form	Maximum Quantity per 30 Days
Aimovig® (erenumab-aooe SC injection)	70 mg/mL prefilled auto-injector/syringe	1 prefilled auto-injector/syringe*
	140 mg/mL prefilled auto-injector/syringe	1 prefilled auto-injector/syringe*

SC – Subcutaneous; * This is a quantity sufficient for a 30-day supply at once monthly dosing.

Criteria

Cigna covers quantities as medically necessary when the following criteria are met:

Aimovig 70 mg/mL prefilled auto-injector/syringe

1. If the individual requires a dose titration from 70 mg once monthly to 140 mg once monthly, approve a one-time override for one 70 mg/mL prefilled syringe or auto-injector.

Note: In other situations where the individual is changing to a 140 mg once monthly dose, the 140 mg/mL syringe/auto-injector should be used.

Aimovig 140 mg/mL prefilled auto-injector/syringe

No overrides recommended.

Conditions Not Covered

Any other exception is considered not medically necessary.

Background

Overview

Aimovig, a calcitonin gene-related peptide (CGRP) receptor antagonist, is indicated for the **preventive treatment of migraine** in adults.¹

Dosing

The recommended dose of Aimovig is 70 mg injected subcutaneously (SC) once monthly.¹ Some patients may benefit from a dose of 140 mg SC once monthly. If a dose of Aimovig is missed, administer as soon as possible. Thereafter, Aimovig can be scheduled monthly from the date of the last dose.

Availability

Aimovig is available as 70 mg/mL and 140 mg/mL single-dose prefilled auto-injectors.¹ Aimovig is also approved to be supplied as 70 mg/mL and 140 mg/mL single-dose prefilled syringes as well. However, the prefilled syringes are not currently available.

References

1. Aimovig® subcutaneous injection [prescribing information]. Thousand Oaks, CA: Amgen; May 2021.

Revision History

Type of Revision	Summary of Changes	Approval Date
Annual Revision	No changes to criteria.	04/21/2022

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc. and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2023 Cigna.